Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026)

Prelude Therapeutics has reported EBITDA Margin for 3 years, with the latest figure at 309.54% in Q1 2026.

• Quarterly EBITDA Margin changed N/A year-over-year to 309.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 503.21% (changed N/A YoY) and the FY2025 annual result came in at 861.33%, up 113458.0% from the prior year.
• EBITDA Margin eased to 309.54% in Q1 2026 per PRLD's latest filing, from 307.59% in the prior quarter.
• Over five years, EBITDA Margin peaked at 307.59% in Q4 2025 and troughed at 1145.87% in Q3 2024.
• A 3-year average of 584.58% and a median of 314.12% in 2025 frame the typical range for EBITDA Margin.
• The widest YoY moves for EBITDA Margin: up 83174 bps in 2025, down 53819 bps in 2025.
• Over 3 years, EBITDA Margin stood at 845.78% in 2024, then soared by 64 bps to 307.59% in 2025, then dropped by 1 bps to 309.54% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 309.54%, 307.59%, and 314.12% for Q1 2026, Q4 2025, and Q3 2025 respectively.